- Home
- VSTM vs MRNS Comparison
VSTM vs MRNS Comparison
Compare VSTM & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- MRNS
- Stock Information
- Founded
- VSTM 2010
- MRNS 2003
- Country
- VSTM United States
- MRNS United States
- Employees
- VSTM N/A
- MRNS N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- MRNS Health Care
- Exchange
- VSTM Nasdaq
- MRNS Nasdaq
- Market Cap
- VSTM 132.0M
- MRNS 104.7M
- IPO Year
- VSTM 2012
- MRNS 2014
- Fundamental
- Price
- VSTM $3.88
- MRNS $0.31
- Analyst Decision
- VSTM Strong Buy
- MRNS Buy
- Analyst Count
- VSTM 8
- MRNS 12
- Target Price
- VSTM $14.57
- MRNS $4.56
- AVG Volume (30 Days)
- VSTM 1.1M
- MRNS 5.7M
- Earning Date
- VSTM 11-06-2024
- MRNS 11-05-2024
- Dividend Yield
- VSTM N/A
- MRNS N/A
- EPS Growth
- VSTM N/A
- MRNS N/A
- EPS
- VSTM N/A
- MRNS N/A
- Revenue
- VSTM $10,000,000.00
- MRNS $30,263,000.00
- Revenue This Year
- VSTM N/A
- MRNS $21.18
- Revenue Next Year
- VSTM $125.69
- MRNS $56.42
- P/E Ratio
- VSTM N/A
- MRNS N/A
- Revenue Growth
- VSTM N/A
- MRNS 16.56
- 52 Week Low
- VSTM $2.10
- MRNS $0.26
- 52 Week High
- VSTM $14.22
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- VSTM 63.77
- MRNS 21.75
- Support Level
- VSTM $3.11
- MRNS $0.29
- Resistance Level
- VSTM $3.76
- MRNS $1.96
- Average True Range (ATR)
- VSTM 0.33
- MRNS 0.12
- MACD
- VSTM 0.04
- MRNS -0.18
- Stochastic Oscillator
- VSTM 94.26
- MRNS 2.41
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.